NIMOTOP

This brand name is authorized in Austria, Canada, Cyprus, Germany, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Malta, Mexico, Netherlands, New Zealand, Poland, Romania, Singapore, Turkey, United Kingdom, South Africa

Active ingredients

The drug NIMOTOP contains one active pharmaceutical ingredient (API):

1 Nimodipine
UNII 57WA9QZ5WH - NIMODIPINE

Nimodipine is a dihydropyridine calcium channel blocker with particular cerebrovascular effect. Nimodipine increases cerebral perfusion, particularly in poorly perfused areas, by arterial dilatation, an effect which is proportionately greater in smaller than in larger vessels.

Read about Nimodipine

Medication package inserts

Below package inserts are available for further reading:

Title Information Source Document Type  
NIMOTOP Film-coated tablet Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC
NIMOTOP 0.02% Solution for infusion Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
C08CA06 Nimodipine C Cardiovascular system → C08 Calcium channel blockers → C08C Selective calcium channel blockers with mainly vascular effects → C08CA Dihydropyridine derivatives
Discover more medicines within C08CA06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: CA Health Products and Food Branch Identifier(s): 02325926
Country: DE Bundesinstitut für Arzneimittel und Medizinprodukte Identifier(s): 00165333, 01549969, 03673254, 06151384
Country: EE Ravimiamet Identifier(s): 1006254, 1006287, 1510221
Country: ES Centro de información online de medicamentos de la AEMPS Identifier(s): 58075
Country: FI Lääkealan turvallisuus- ja kehittämiskeskus Identifier(s): 086553, 086587
Country: FR Base de données publique des médicaments Identifier(s): 61339638, 65726536
Country: GB Medicines & Healthcare Products Regulatory Agency Identifier(s): 373063, 38794
Country: HK Department of Health Drug Office Identifier(s): 28973, 28974
Country: HR Agencija za lijekove i medicinske proizvode Identifier(s): HR-H-331612666, HR-H-637102533
Country: IE Health Products Regulatory Authority Identifier(s): 36517
Country: MT Medicines Authority Identifier(s): AA639/02402, MA639/02401
Country: MX Comisión Federal para la Protección contra Riesgos Sanitarios Identifier(s): 122M88, 123M88
Country: NL Z-Index G-Standaard Identifier(s): 13484494
Country: NL Z-Index G-Standaard, PRK Identifier(s): 27588, 27596
Country: NZ Medicines and Medical Devices Safety Authority Identifier(s): 6608, 6609
Country: PL Rejestru Produktów Leczniczych Identifier(s): 100034556, 100047470, 100247447, 100264180, 100293252, 100293648, 100323869, 100332259, 100363490, 100396006, 100421247, 100423677, 100425311, 100465827
Country: RO Agenția Națională a Medicamentului și a Dispozitivelor Medicale Identifier(s): W63887001, W63887002, W63888001, W63888002, W63888003, W63888004
Country: SG Health Sciences Authority Identifier(s): 06931P, 09111P
Country: TR İlaç ve Tıbbi Cihaz Kurumu Identifier(s): 8699546010387, 8699546750399
Country: ZA Health Products Regulatory Authority Identifier(s): T/7.1/229, T/7.1/230

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.